

Neutrophils are not consistently activated by antineutrophil cytoplasmic antibodies in vitro

Antineutrophil cytoplasmic antibody (ANCA) vasculitis is characterised by autoantibodies against myeloperoxidase (MPO) and proteinase 3 (PR3). The evidence that ANCA are pathogenic comes from in vitro studies in which IgG from patients with anti-MPO or anti-PR3 antibodies activate neutrophils to undergo respiratory burst and degranulation. Furthermore, murine monoclonal antibodies against human MPO and PR3 and a chimeric humanised anti-PR3 monoclonal antibody activate neutrophils. The paradigm of neutrophil activation by ANCA has therefore become established.¹ Further support for the pathogenicity of ANCA comes from in vivo studies in which injection of anti-MPO antibodies causes focal necrotising crescentic glomerulonephritis in mice.²

We assessed the effect of purified ANCA on the activation of TNF α primed neutrophils using 10 control IgGs, 11 MPO-ANCA and 9 PR3-ANCA using two different assays of the neutrophil respiratory burst (full methods are in a online supplementary file 1). We found no significant difference in two separate neutrophil donors (figure 1A-C). We also used assays for four markers of neutrophil degranulation and found no differences in two neutrophil donors (figure 1D-G). The results are not due to inactivity of the purified ANCA IgG preparations. Aliquots of the same ANCA and control IgG batches were used in a recent publication where we demonstrated clear effects of these ANCA IgG preparations on monocytes, in experiments performed with during the same period of time.³

Our data challenge the established paradigm of neutrophil activation by ANCA. It is not clear why our results differ from others, but note that most previous publications have included small numbers which might lead to chance effects and selection bias. The ability of ANCA to activate neutrophils may be affected by affinity. We did not measure affinity or explore this possibility. We reviewed the literature to find publications in which six or more MPO-ANCA or PR3-ANCA IgG samples were compared with a similar number of control IgG samples and found only two. Franssen *et al* compared IgG purified from 17 PR3-ANCA positive patients, 14 MPO-ANCA positive patients and 16 controls. The patients were consecutive, eliminating selection bias.⁴ These authors found no significant effect of MPO-ANCA IgG on neutrophil respiratory burst using the DHR 123 and ferricytochrome C assays, and no effect on degranulation as measured by glucuronidase and lactoferrin release. There was an effect for PR3-ANCA which, although statistically significant, was small in magnitude. In all cases, the level of activation was much less than with N-formylmethionine-leucyl-phenylalanine. Harper *et al* compared 23 MPO-ANCAs, 15 PR3 ANCAs and 8 control IgGs using ferricytochrome C, calcium flux and MPO release assays.⁵ Both MPO-ANCA and PR3-ANCA caused significant activation compared with control IgG. However, in contrast to the study by Franssen *et al*, MPO-ANCA had a greater effect.

A recent report consistent with our data suggests that ANCA IgG does not activate neutrophils in vitro.⁶ Kraaij *et al* showed that serum from patients with ANCA vasculitis induced neutrophil extracellular traps (NET) formation, but this was unaffected by IgG depletion. In addition, purified IgG was unable to induce NET formation. This suggested that factors in the serum of patients with vasculitis, other than IgG, could activate neutrophils. This raises the possibility that the purity of IgG preparations could

have influenced results in previous studies. We emphasise that our data do not exclude a role for neutrophils in the pathogenesis of ANCA vasculitis. ANCA may have direct or indirect effects on neutrophils in vivo that are not evident using in vitro assays of activation. We also acknowledge that there are many previous publications suggesting that ANCA do activate neutrophils in vitro and encourage other investigators to re-examine this question.

Reena J Popat, Michael G Robson

School of Immunology and Microbial Sciences, King's College London, London, UK

Correspondence to Dr Michael G Robson, School of Immunology and Microbial Sciences, King's College London, London WC2R 2LS, UK; michael.robson@kcl.ac.uk

Correction notice This article has been corrected since it published Online First. The last sentence has been amended.

Handling editor Josef S Smolen

Acknowledgements We are grateful to patients and colleagues at Kent and Canterbury Hospital, Royal Sussex County Hospital, King's College Hospital, St. Helier Hospital and Guy's and St. Thomas' Hospital for help obtaining patient samples.

Contributors MGR designed the experiments, analysed data and wrote the paper. RJP designed and performed experiments, analysed data and edited the paper. Both authors approved the final version.

Funding This work was funded by an MRC/Kidney research clinical training fellowship to RP (MR/K000977/1). The research was also supported by the Medical Research Council (MRC) Centre for Transplantation, King's College London, UK (MRC grant MR/J006742/1) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust and King's College London.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests None declared.

Patient consent Blood samples were taken following informed consent.

Ethics approval NRES committee London—London Bridge 09/H084/72.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data will be shared following any reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2018-214405>).



To cite Popat RJ, Robson MG. *Ann Rheum Dis* 2019;**78**:709–711.

Received 6 September 2018

Accepted 5 November 2018

Published Online First 4 December 2018




Figure 1 ANCA does not stimulate the neutrophil respiratory burst or degranulation in vitro. Ten control IgG, 11 MPO-ANCA and 9 PR3-ANCA were tested, with experiments performed in two neutrophil donors. The respiratory burst was assessed with (A) a dihydrorhodamine 123 assay of hydrogen peroxide generation, (B–C) luminol and isoluminol-based assays of total and extracellular superoxide generation. Degranulation products measured were (D) soluble MPO (azurophilic granules), (E) soluble lactoferrin (specific granules), (F) cell surface CD66b (specific granules) and (G) cell surface CD11b (secretory, gelatinase and specific granules). In (B–C), data shown are the peak response. For fMLP, this occurred at approximately 2 min, whereas the peak response to IgG was at approximately 30 min. There were no significant differences between the groups for any of the assays. ANCA, antineutrophil cytoplasmic antibody; fMLP, N-formylmethionine-leucyl-phenylalanine; NA, not activated.

Ann Rheum Dis 2019;**78**:709–711. doi:10.1136/annrheumdis-2018-214405

REFERENCES

- 1 Kettritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. *Clin Exp Immunol* 2012;**169**:220–8.
- 2 Xiao H, Heeringa P, Hu P, *et al*. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *J Clin Invest* 2002;**110**:955–63.
- 3 Popat RJ, Hakki S, Thakker A, *et al*. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. *JCI Insight* 2017;**2**:e87379.
- 4 Franssen CF, Huitema MG, Muller Kobold AC, *et al*. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. *J Am Soc Nephrol* 1999;**10**:1506–15.
- 5 Harper L, Radford D, Plant T, *et al*. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytoplasmic antibody-positive patients. *Arthritis Rheum* 2001;**44**:921–30.
- 6 Kraaij T, Kamerling SWA, van Dam LS, *et al*. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. *Kidney Int* 2018;**94**:139–49.